Improvements O
can O
be O
made O
in O
the O
quality O
of O
cancer O
care O
if O
supportive O
care O
needs O
are O
addressed O
";" O
however O
, O
there O
are O
few O
trials O
of O
supportive O
care O
interventions O
to O
guide O
policy O
and O
practice O
. O

The B-Premise
KPS I-Premise
score I-Premise
in I-Premise
the I-Premise
treated I-Premise
group I-Premise
after I-Premise
treatment I-Premise
was I-Premise
improved I-Premise
in I-Premise
13 I-Premise
patients I-Premise
( I-Premise
23.6 I-Premise
% I-Premise
) I-Premise
, I-Premise
stabilized I-Premise
in I-Premise
27 I-Premise
( I-Premise
49.6 I-Premise
% I-Premise
) I-Premise
and I-Premise
declined I-Premise
in I-Premise
15 I-Premise
( I-Premise
27.3 I-Premise
% I-Premise
) I-Premise
, I-Premise
while I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
it I-Premise
was I-Premise
improved I-Premise
in I-Premise
7 I-Premise
( I-Premise
13.2 I-Premise
% I-Premise
) I-Premise
, I-Premise
stabilized I-Premise
in I-Premise
21 I-Premise
( I-Premise
39.6 I-Premise
% I-Premise
) I-Premise
and I-Premise
declined I-Premise
in I-Premise
25 I-Premise
( I-Premise
47.2 I-Premise
% I-Premise
) I-Premise
, I-Premise
the I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
was I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

All O
statistical O
tests O
were O
two-sided O
and O
were O
performed O
at O
the O
alpha O
= O
. O

No B-Premise
significant I-Premise
longitudinal I-Premise
changes I-Premise
were I-Premise
detected I-Premise
in I-Premise
the I-Premise
global I-Premise
health I-Premise
status I-Premise
in I-Premise
both I-Premise
groups I-Premise
upon I-Premise
available I-Premise
follow-up I-Premise
. I-Premise

Participants B-Premise
randomized I-Premise
to I-Premise
the I-Premise
exercise I-Premise
group I-Premise
increased I-Premise
physical I-Premise
activity I-Premise
by I-Premise
more I-Premise
than I-Premise
100 I-Premise
versus I-Premise
22 I-Premise
% I-Premise
in I-Premise
controls I-Premise
( I-Premise
54.5 I-Premise
vs. I-Premise
14.6 I-Premise
min I-Premise
, I-Premise
P I-Premise
= I-Premise
0.13 I-Premise
) I-Premise
, I-Premise
and I-Premise
experienced I-Premise
significant I-Premise
increases I-Premise
in I-Premise
fitness I-Premise
( I-Premise
increased I-Premise
6-min I-Premise
walk I-Premise
test I-Premise
distance I-Premise
by I-Premise
186.9 I-Premise
vs. I-Premise
81.9 I-Premise
feet I-Premise
, I-Premise
P I-Premise
= I-Premise
0.006 I-Premise
) I-Premise
and I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
7.1 I-Premise
vs. I-Premise
2.6 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
as I-Premise
compared I-Premise
to I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

However O
, O
the O
early B-Claim
postoperative I-Claim
outcome I-Claim
does I-Claim
not I-Claim
give I-Claim
a I-Claim
complete I-Claim
answer I-Claim
and O
the B-Claim
eventual I-Claim
cost-effectiveness I-Claim
will I-Claim
only I-Claim
become I-Claim
clear I-Claim
after I-Claim
long-term I-Claim
follow-up I-Claim
. I-Claim

There B-Premise
were I-Premise
three I-Premise
treatment-related I-Premise
deaths I-Premise
with I-Premise
CAF I-Premise
but B-Premise
none I-Premise
with I-Premise
the I-Premise
16-week I-Premise
regimen I-Premise
. I-Premise

The B-Premise
incidence I-Premise
of I-Premise
toxicity I-Premise
in I-Premise
the I-Premise
groups I-Premise
was I-Premise
similar I-Premise
. I-Premise

We O
conducted O
a O
randomized O
trial O
comparing O
uterine-artery O
embolization O
and O
surgery O
in O
women O
with O
symptomatic O
uterine O
fibroids O
. O

Patients O
were O
interviewed O
by O
telephone O
before O
treatment O
( O
baseline O
) O
, O
midtreatment O
, O
within O
1 O
month O
post-treatment O
, O
and O
at O
12 O
, O
18 O
, O
and O
24 O
months O
postbaseline O
by O
using O
questionnaires O
from O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
, O
a O
breast O
systemic O
adverse O
effects O
scale O
( O
EORTC O
BR23 O
) O
, O
and O
the O
Hospital O
Anxiety O
and O
Depression O
Scale O
( O
HADS O
) O
. O

Multivariate O
analyses O
were O
performed O
for O
both O
OS O
and O
LRC O
. O

The B-Premise
-1 I-Premise
, I-Premise
-2 I-Premise
, I-Premise
and I-Premise
3-year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
88.9 I-Premise
% I-Premise
, I-Premise
44.4 I-Premise
% I-Premise
, I-Premise
and I-Premise
16.7 I-Premise
% I-Premise
for I-Premise
the I-Premise
vaccine I-Premise
group I-Premise
, I-Premise
respectively I-Premise
, I-Premise
and I-Premise
75.0 I-Premise
% I-Premise
, I-Premise
18.8 I-Premise
% I-Premise
, I-Premise
and I-Premise
0 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
( I-Premise
P I-Premise
= I-Premise
0.299 I-Premise
, I-Premise
0.0035 I-Premise
, I-Premise
0.0014 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

A O
multicenter O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
was O
conducted O
. O

A B-Claim
peer-modeling I-Claim
videotape I-Claim
can I-Claim
accelerate I-Claim
the I-Claim
recovery I-Claim
of I-Claim
energy I-Claim
during I-Claim
the I-Claim
re-entry I-Claim
phase I-Claim
in I-Claim
women I-Claim
treated I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
particularly I-Claim
among I-Claim
those I-Claim
who I-Claim
feel I-Claim
less I-Claim
prepared I-Claim
for I-Claim
re-entry I-Claim
. I-Claim

Thirty-eight B-Premise
patients I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
and I-Premise
58 I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
, I-Premise
suffered I-Premise
breakthrough I-Premise
pain I-Premise
on I-Premise
day I-Premise
3 I-Premise
( I-Premise
P I-Premise
< I-Premise
0Â·001 I-Premise
) I-Premise
. I-Premise

Gemcitabine O
( O
G O
) O
is O
standard O
therapy O
for O
pancreatic O
cancer O
. O

Over O
the O
next O
24 O
months O
, O
oral O
lesion O
size O
and O
number O
, O
pain O
, O
and O
quality O
of O
life O
were O
assessed O
. O

Drowsiness B-Premise
, I-Premise
confusion I-Premise
and I-Premise
dry I-Premise
mouth I-Premise
were I-Premise
significantly I-Premise
more I-Premise
intense I-Premise
with I-Premise
amitriptyline I-Premise
than I-Premise
with I-Premise
placebo I-Premise
( I-Premise
P I-Premise
< I-Premise
0.036 I-Premise
, I-Premise
0.003 I-Premise
, I-Premise
and I-Premise
0.034 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Neither B-Premise
surgery I-Premise
nor I-Premise
definitive I-Premise
CRT I-Premise
significantly I-Premise
impaired I-Premise
the I-Premise
global I-Premise
health I-Premise
status I-Premise
of I-Premise
patients I-Premise
. I-Premise

According B-Premise
to I-Premise
the I-Premise
Radiation I-Premise
Therapy I-Premise
Oncology I-Premise
Group I-Premise
scale I-Premise
, I-Premise
the I-Premise
Grade I-Premise
2 I-Premise
or I-Premise
greater I-Premise
rectal I-Premise
toxicity I-Premise
rate I-Premise
was I-Premise
14 I-Premise
% I-Premise
and I-Premise
19.5 I-Premise
% I-Premise
for I-Premise
the I-Premise
-70 I-Premise
and I-Premise
80-Gy I-Premise
arms I-Premise
( I-Premise
p I-Premise
= I-Premise
.22 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Results B-Claim
showed I-Claim
a I-Claim
significant I-Claim
increase I-Claim
in I-Claim
pain I-Claim
knowledge I-Claim
in I-Claim
patients I-Claim
who I-Claim
received I-Claim
the I-Claim
Pain I-Claim
Education I-Claim
Program I-Claim
and I-Claim
a I-Claim
significant I-Claim
decrease I-Claim
in I-Claim
pain I-Claim
intensity I-Claim
. I-Claim

Cox B-Premise
multivariate I-Premise
analysis I-Premise
showed I-Premise
paclitaxel I-Premise
plus I-Premise
supportive I-Premise
care I-Premise
to I-Premise
be I-Premise
statistically I-Premise
significantly I-Premise
associated I-Premise
with I-Premise
improved I-Premise
survival I-Premise
( I-Premise
two-sided I-Premise
P I-Premise
=.048 I-Premise
) I-Premise
. I-Premise

Care O
closer O
to O
home O
is O
being O
explored O
as O
a O
means O
of O
improving O
patient O
experience O
as O
well O
as O
efficiency O
in O
terms O
of O
cost O
savings O
. O

In B-Claim
conclusion I-Claim
, I-Claim
we I-Claim
were I-Claim
unable I-Claim
to I-Claim
identify I-Claim
a I-Claim
reduction I-Claim
in I-Claim
radiation-induced I-Claim
mucositis I-Claim
in I-Claim
patients I-Claim
receiving I-Claim
misoprostol I-Claim
. I-Claim

We O
investigated O
the O
role O
of O
tamoxifen O
and O
radiotherapy O
( O
RT O
) O
for O
the O
prevention O
and O
treatment O
of O
gynecomastia O
and O
breast O
pain O
during O
adjuvant O
bicalutamide O
monotherapy O
after O
radical O
prostatectomy O
( O
RP O
) O
in O
patients O
with O
prostate O
cancer O
. O

Three O
hundred O
two O
outpatients O
with O
breast O
cancer O
participated O
. O

The B-Premise
linear I-Premise
analogue I-Premise
self-assessment I-Premise
scale I-Premise
was I-Premise
less I-Premise
but I-Premise
significantly I-Premise
efficient I-Premise
for I-Premise
detection I-Premise
of I-Premise
treatment I-Premise
effects I-Premise
, I-Premise
with I-Premise
relative I-Premise
efficiency I-Premise
estimates I-Premise
ranging I-Premise
from I-Premise
0.16 I-Premise
to I-Premise
2.45 I-Premise
and I-Premise
a I-Premise
median I-Premise
of I-Premise
0.66 I-Premise
among I-Premise
the I-Premise
comparisons I-Premise
with I-Premise
relatively I-Premise
stable I-Premise
estimates I-Premise
( I-Premise
/t/ I-Premise
> I-Premise
or I-Premise
= I-Premise
1.0 I-Premise
) I-Premise
and I-Premise
more I-Premise
efficient I-Premise
for I-Premise
recurrence I-Premise
than I-Premise
the I-Premise
adjective I-Premise
checklist I-Premise
. I-Premise

Eighty-nine O
chemotherapy-naÃ¯ve O
patients O
were O
randomized O
either O
to O
gemcitabine O
( O
1,000 O
mg/m2 O
, O
30-min O
infusion O
on O
days O
1 O
, O
8 O
and O
15 O
) O
and O
oral O
etoposide O
( O
50 O
mg O
, O
days O
1-14 O
";" O
GE O
group O
) O
or O
gemcitabine O
at O
the O
same O
schedule O
and O
cisplatin O
( O
75 O
mg/m2 O
on O
day O
15 O
";" O
GP O
group O
) O
. O

The O
study O
was O
carried O
out O
by O
a O
multi-institutional O
cooperative O
group O
in O
chemotherapy-naive O
stage O
IIIB O
to O
IV O
NSCLC O
patients O
randomized O
to O
receive O
paclitaxel O
plus O
cisplatin O
or O
etoposide O
plus O
cisplatin O
. O

The O
mean O
follow-up O
period O
was O
53.6 O
months O
. O

Of O
these O
, O
433 O
are O
known O
to O
be O
dead O
, O
26 O
are O
lost O
to O
follow-up O
and O
11 O
are O
still O
alive O
. O

Poor B-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
between I-Premise
two I-Premise
groups I-Premise
was I-Premise
observed I-Premise
at I-Premise
1 I-Premise
month I-Premise
( I-Premise
23.9 I-Premise
% I-Premise
vs. I-Premise
13 I-Premise
% I-Premise
) I-Premise
and I-Premise
2 I-Premise
months I-Premise
( I-Premise
15.8 I-Premise
% I-Premise
vs. I-Premise
3.7 I-Premise
% I-Premise
) I-Premise
after I-Premise
chemotherapy I-Premise
. I-Premise

Those O
who O
received O
prednisone O
alone O
could O
have O
mitoxantrone O
added O
after O
6 O
weeks O
if O
there O
was O
no O
improvement O
in O
pain O
. O

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
56Â·9 I-Premise
months I-Premise
( I-Premise
IQR I-Premise
37Â·4-81Â·8 I-Premise
) I-Premise
from I-Premise
randomisation I-Premise
and I-Premise
370 I-Premise
deaths I-Premise
( I-Premise
186 I-Premise
early I-Premise
, I-Premise
184 I-Premise
delayed I-Premise
) I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
evidence I-Premise
of I-Premise
a I-Premise
difference I-Premise
in I-Premise
overall I-Premise
survival I-Premise
between I-Premise
early I-Premise
and I-Premise
delayed I-Premise
treatment I-Premise
( I-Premise
HR I-Premise
0Â·98 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0Â·80-1Â·20 I-Premise
, I-Premise
p=0Â·85 I-Premise
) I-Premise
. I-Premise

Opioids O
, O
on O
their O
own O
, O
do O
not O
control O
this O
type O
of O
pain O
well O
enough O
, O
and O
co-analgesics O
are O
necessary O
. O

Most B-Claim
patients I-Claim
with I-Claim
advanced I-Claim
ovarian I-Claim
cancer I-Claim
develop I-Claim
recurrent I-Claim
disease I-Claim
. I-Claim

The O
combination O
of O
cisplatin O
with O
Mitomycin O
and O
Vinblastine O
was O
one O
of O
the O
most O
frequently O
used O
in O
the O
palliative O
setting O
at O
the O
time O
of O
design O
of O
our O
study O
. O

The O
experimental O
intervention O
consisted O
of O
reporting O
data O
from O
the O
standardized O
assessments O
to O
the O
IDTs O
. O

Three O
patients O
were O
ineligible O
. O

Objective B-Premise
response I-Premise
rate I-Premise
was I-Premise
similar I-Premise
for I-Premise
fulvestrant I-Premise
500 I-Premise
mg I-Premise
and I-Premise
250 I-Premise
mg I-Premise
( I-Premise
9.1 I-Premise
% I-Premise
v I-Premise
10.2 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Group B-Premise
CBT I-Premise
significantly I-Premise
reduced I-Premise
HFNS I-Premise
problem I-Premise
rating I-Premise
at I-Premise
9 I-Premise
weeks I-Premise
after I-Premise
randomisation I-Premise
compared I-Premise
with I-Premise
usual I-Premise
care I-Premise
( I-Premise
mean I-Premise
difference I-Premise
-1Â·67 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-2Â·43 I-Premise
to I-Premise
-0Â·91 I-Premise
";" I-Premise
p I-Premise
< I-Premise
0Â·0001 I-Premise
) I-Premise
and I-Premise
improvements I-Premise
were I-Premise
maintained I-Premise
at I-Premise
26 I-Premise
weeks I-Premise
( I-Premise
mean I-Premise
difference I-Premise
-1Â·76 I-Premise
, I-Premise
-2Â·54 I-Premise
to I-Premise
-0Â·99 I-Premise
";" I-Premise
p I-Premise
< I-Premise
0Â·0001 I-Premise
) I-Premise
. I-Premise

Survival O
curves O
were O
calculated O
using O
the O
Kaplan-Meier O
method O
, O
and O
hazard O
ratios O
were O
estimated O
using O
the O
Cox O
proportional O
hazards O
model O
. O

Many B-Premise
patients I-Premise
( I-Premise
24 I-Premise
% I-Premise
) I-Premise
failed I-Premise
to I-Premise
complete I-Premise
at I-Premise
least I-Premise
6 I-Premise
weeks I-Premise
of I-Premise
therapy I-Premise
, I-Premise
including I-Premise
five I-Premise
( I-Premise
8 I-Premise
% I-Premise
) I-Premise
treatment-related I-Premise
early I-Premise
deaths I-Premise
. I-Premise

This O
study O
is O
registered O
as O
an O
international O
standard O
randomised O
controlled O
trial O
, O
number O
ISRCTN01534787 O
. O

Hence O
, O
nurse-led B-Claim
telephone I-Claim
follow-up I-Claim
seems I-Claim
an I-Claim
appropriate I-Claim
way I-Claim
to I-Claim
reduce I-Claim
clinic I-Claim
visits I-Claim
and I-Claim
represents I-Claim
an I-Claim
accepted I-Claim
alternative I-Claim
strategy I-Claim
. I-Claim

Toxicity B-Premise
was I-Premise
generally I-Premise
limited I-Premise
to I-Premise
musculoskeletal I-Premise
symptoms I-Premise
( I-Premise
18 I-Premise
% I-Premise
grade I-Premise
3/4 I-Premise
for I-Premise
marimastat I-Premise
) I-Premise
. I-Premise

The B-Premise
overall I-Premise
progression-free I-Premise
survival I-Premise
rate I-Premise
was I-Premise
53 I-Premise
% I-Premise
at I-Premise
1 I-Premise
year I-Premise
and I-Premise
17 I-Premise
% I-Premise
at I-Premise
3 I-Premise
years I-Premise
. I-Premise

Increased B-Claim
expression I-Claim
of I-Claim
metalloproteinases I-Claim
is I-Claim
associated I-Claim
with I-Claim
poor I-Claim
prognosis I-Claim
in I-Claim
small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
SCLC I-Claim
) I-Claim
. I-Claim

Patients B-Premise
on I-Premise
marimastat I-Premise
had I-Premise
significantly I-Premise
poorer I-Premise
quality I-Premise
of I-Premise
life I-Premise
at I-Premise
3 I-Premise
and I-Premise
6 I-Premise
months I-Premise
. I-Premise

Randomized O
controlled O
trial O
. O

QOL O
was O
assessed O
by O
using O
the O
Edmonton O
Symptom O
Assessment O
Scale O
( O
ESAS O
) O
and O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
( O
FACT O
) O
-Anemia O
questionnaires O
. O

A O
multidimensional O
rehabilitation O
program O
for O
cancer O
survivors O
was O
developed O
to O
overcome O
cancer-related O
problems O
and O
to O
improve O
quality O
of O
life O
. O

Exercise O
, O
fatigue O
, O
and O
QOL O
. O

The O
participants O
who O
dropped O
out O
pretreatment O
reported O
less O
financial O
concerns O
than O
post-treatment O
dropouts O
, O
and O
the O
participants O
who O
dropped O
out O
of O
the O
study O
midtreatment O
had O
poorer O
physical O
health O
than O
treatment O
completers O
. O

Primary O
efficacy O
endpoints O
were O
times O
to O
treatment O
failure O
and O
objective O
disease O
progression O
and O
survival O
. O

However O
, O
there B-Claim
was I-Claim
a I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
secondary I-Claim
endpoints I-Claim
of I-Claim
clinically I-Claim
assessed I-Claim
OPS I-Claim
and I-Claim
DNA I-Claim
concentration I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
in I-Claim
H I-Claim
& I-Claim
N I-Claim
cancer I-Claim
patients I-Claim
treated I-Claim
with I-Claim
CRT I-Claim
. I-Claim

Everolimus O
( O
EVE O
) O
+exemestane O
( O
EXE O
";" O
n O
= O
485 O
) O
more O
than O
doubled O
median O
progression-free O
survival O
versus O
placebo O
( O
PBO O
) O
+ O
EXE O
( O
n O
= O
239 O
) O
, O
with O
a O
manageable O
safety O
profile O
and O
no O
deterioration O
in O
health-related O
quality-of-life O
( O
HRQOL O
) O
in O
patients O
with O
hormone-receptor-positive O
( O
HR O
( O
+ O
) O
) O
advanced O
breast O
cancer O
( O
ABC O
) O
who O
recurred O
or O
progressed O
on/after O
nonsteroidal O
aromatase O
inhibitor O
( O
NSAI O
) O
therapy O
. O

Fifty O
eight O
of O
the O
60 O
randomized O
patients O
who O
filled O
the O
QOL O
questionnaire O
at O
least O
at O
one O
time O
point O
were O
included O
in O
the O
analysis O
. O

Women B-Claim
with I-Claim
breast I-Claim
cancer I-Claim
may I-Claim
have I-Claim
an I-Claim
even I-Claim
higher I-Claim
risk I-Claim
of I-Claim
depression I-Claim
particularly I-Claim
in I-Claim
a I-Claim
postmenopausal I-Claim
or I-Claim
estrogen I-Claim
deficiency I-Claim
state I-Claim
. I-Claim

These B-Claim
findings I-Claim
provide I-Claim
evidence I-Claim
for I-Claim
the I-Claim
short-term I-Claim
benefits I-Claim
of I-Claim
minimally I-Claim
invasive I-Claim
oesophagectomy I-Claim
for I-Claim
patients I-Claim
with I-Claim
resectable I-Claim
oesophageal I-Claim
cancer I-Claim
. I-Claim

Only B-Premise
the I-Premise
FACT-G I-Premise
social/family I-Premise
well-being I-Premise
subscale I-Premise
had I-Premise
no I-Premise
relationship I-Premise
with I-Premise
EQ-5D I-Premise
responses I-Premise
and I-Premise
utility I-Premise
scores I-Premise
. I-Premise

Age-adjusted B-Claim
risk I-Claim
profiles I-Claim
that I-Claim
consider I-Claim
patient-reported I-Claim
outcomes I-Claim
enable I-Claim
patients I-Claim
to I-Claim
adapt I-Claim
to I-Claim
their I-Claim
disease I-Claim
and I-Claim
treatment I-Claim
, I-Claim
such I-Claim
as I-Claim
considering I-Claim
the I-Claim
trade-offs I-Claim
between I-Claim
delayed I-Claim
endocrine I-Claim
symptoms I-Claim
, I-Claim
but I-Claim
higher I-Claim
risk I-Claim
of I-Claim
permanent I-Claim
menopause I-Claim
with I-Claim
chemotherapy I-Claim
, I-Claim
and I-Claim
immediate I-Claim
but I-Claim
reversible I-Claim
endocrine I-Claim
symptoms I-Claim
with I-Claim
goserelin I-Claim
, I-Claim
in I-Claim
younger I-Claim
premenopausal I-Claim
patients I-Claim
. I-Claim

Tertiary O
care O
, O
academic O
medical O
center O
. O

The O
combination O
of O
radiotherapy O
plus O
long-term O
medical O
suppression O
of O
androgens O
( O
> O
or O
= O
2 O
years O
) O
improves O
overall O
survival O
in O
patients O
with O
locally O
advanced O
prostate O
cancer O
. O

Toxicity O
was O
evaluated O
according O
to O
the O
NCI-CTC O
version O
2.0 O
. O

TSS B-Premise
improved I-Premise
in I-Premise
49 I-Premise
patients I-Premise
( I-Premise
77 I-Premise
% I-Premise
) I-Premise
on I-Premise
regimen I-Premise
1 I-Premise
, I-Premise
and I-Premise
in I-Premise
57 I-Premise
( I-Premise
92 I-Premise
% I-Premise
) I-Premise
patients I-Premise
on I-Premise
regimen I-Premise
2 I-Premise
, I-Premise
a I-Premise
difference I-Premise
of I-Premise
15 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
3-28 I-Premise
) I-Premise
in I-Premise
the I-Premise
proportion I-Premise
improving I-Premise
between I-Premise
the I-Premise
two I-Premise
regimens I-Premise
. I-Premise

There B-Premise
was I-Premise
significantly I-Premise
more I-Premise
grade I-Premise
3-4 I-Premise
neutropenia I-Premise
( I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
and I-Premise
dyspnea I-Premise
( I-Premise
P I-Premise
= I-Premise
.014 I-Premise
) I-Premise
with I-Premise
PB+G I-Premise
. I-Premise

To O
confirm O
its O
concurrent O
validity O
and O
responsiveness O
to O
treatment O
and O
recurrence O
in O
patients O
with O
breast O
cancer O
, O
emotional O
well-being O
was O
assessed O
every O
3 O
months O
for O
2 O
years O
and O
at O
1 O
and O
6 O
months O
after O
recurrence O
in O
1,169 O
patients O
who O
were O
premenopausal O
and O
960 O
patients O
who O
were O
postmenopausal O
. O

Symptomatic B-Premise
response I-Premise
during I-Premise
the I-Premise
first I-Premise
four I-Premise
weeks I-Premise
was I-Premise
seen I-Premise
after I-Premise
pamidronate I-Premise
, I-Premise
but I-Premise
not I-Premise
with I-Premise
placebo I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

The O
starting O
dosage O
was O
60 O
mg/m O
( O
2 O
) O
, O
which O
was O
escalated O
to O
90 O
mg/m O
( O
2 O
) O
and O
then O
120 O
mg/m O
( O
2 O
) O
if O
the O
drug O
was O
well O
tolerated O
( O
< O
or= O
Grade O
2 O
toxicities O
[ O
according O
to O
the O
Southwest O
Oncology O
Group O
toxicity O
scale O
] O
) O
. O

Additional B-Claim
studies I-Claim
of I-Claim
DPPE I-Claim
are I-Claim
warranted I-Claim
. I-Claim

Self-reported B-Premise
severity I-Premise
of I-Premise
facial I-Premise
hair I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
51 I-Premise
) I-Premise
fell I-Premise
from I-Premise
7.3 I-Premise
to I-Premise
3.6 I-Premise
over I-Premise
the I-Premise
6-month I-Premise
study I-Premise
period I-Premise
";" I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
37 I-Premise
) I-Premise
the I-Premise
corresponding I-Premise
scores I-Premise
were I-Premise
7.1 I-Premise
and I-Premise
6.1 I-Premise
. I-Premise

Baseline O
characteristics O
in O
the O
HRQoL O
sub-protocol O
were O
well O
balanced O
between O
the O
anastrozole O
( O
n O
= O
335 O
) O
and O
tamoxifen O
( O
n O
= O
347 O
) O
groups O
in O
the O
primary O
analysis O
population O
. O

At B-Premise
four I-Premise
weeks I-Premise
, I-Premise
patients I-Premise
who I-Premise
received I-Premise
thalidomide I-Premise
had I-Premise
gained I-Premise
on I-Premise
average I-Premise
0.37 I-Premise
kg I-Premise
in I-Premise
weight I-Premise
and I-Premise
1.0 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
in I-Premise
arm I-Premise
muscle I-Premise
mass I-Premise
( I-Premise
AMA I-Premise
) I-Premise
compared I-Premise
with I-Premise
a I-Premise
loss I-Premise
of I-Premise
2.21 I-Premise
kg I-Premise
( I-Premise
absolute I-Premise
difference I-Premise
-2.59 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
-4.3 I-Premise
to I-Premise
-0.8 I-Premise
) I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.005 I-Premise
) I-Premise
and I-Premise
4.46 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
( I-Premise
absolute I-Premise
difference I-Premise
-5.6 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-8.9 I-Premise
to I-Premise
-2.2 I-Premise
) I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

The O
setting O
was O
breast O
cancer O
clinics O
in O
cancer O
centres O
in O
the O
UK O
. O

We O
randomly O
assigned O
56 O
patients O
to O
the O
open O
oesophagectomy O
group O
and O
59 O
to O
the O
minimally O
invasive O
oesophagectomy O
group O
. O

All O
patients O
who O
underwent O
randomisation O
were O
included O
in O
analyses O
. O

Because O
of O
the O
small O
study O
population O
, O
only O
initial O
hospital O
costs O
would O
have O
been O
statistically O
significant O
if O
the O
Bonferroni O
correction O
for O
multiple O
testing O
had O
been O
applied O
. O

The O
primary O
endpoint O
was O
increase O
in O
arm O
volume O
from O
baseline O
to O
the O
average O
of O
measurements O
at O
6 O
and O
12 O
months O
. O

The O
European O
Study O
Group O
for O
Pancreatic O
Cancer O
( O
ESPAC-1 O
) O
study O
is O
the O
largest O
study O
of O
adjuvant O
treatment O
for O
pancreatic O
ductal O
adenocarcinoma O
to O
date O
and O
confirmed O
a O
survival O
advantage O
for O
adjuvant O
chemotherapy O
but O
not O
for O
chemoradiation O
. O

Psychosocial O
stress O
was O
measured O
using O
the O
Symptoms O
Checklist-90-Revised O
, O
and O
quality O
of O
life O
was O
measured O
using O
the O
Medical O
Outcomes O
Study O
Short-Form O
Health O
Survey O
at O
baseline O
, O
immediately O
post-intervention O
, O
and O
at O
6 O
months O
. O

Survival O
was O
the O
primary O
end O
point O
with O
a O
33 O
% O
improvement O
relative O
to O
PC O
considered O
important O
( O
85 O
% O
power O
, O
alpha O
= O
5 O
% O
) O
. O

A B-Claim
carboplatin I-Claim
containing I-Claim
regimen I-Claim
with I-Claim
better I-Claim
toxicity I-Claim
profile I-Claim
and I-Claim
a I-Claim
similar I-Claim
potentiality I-Claim
for I-Claim
symptoms I-Claim
control I-Claim
offers I-Claim
an I-Claim
option I-Claim
in I-Claim
comparison I-Claim
to I-Claim
similar I-Claim
cisplatin I-Claim
containing I-Claim
combinations I-Claim
in I-Claim
the I-Claim
palliative I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Patients O
performed O
5 O
targeted O
swallowing O
exercises O
throughout O
their O
CRT O
and O
participated O
in O
weekly O
swallowing O
therapy O
sessions O
to O
promote O
adherence O
and O
accurate O
technique O
. O

To O
determine O
1-year O
outcomes O
of O
a O
four-component O
behavioral O
therapy O
( O
BT O
) O
sleep O
intervention O
( O
Individualized O
Sleep O
Promotion O
Plan O
[ O
ISPP O
] O
) O
versus O
a O
healthy O
eating O
control O
( O
HEC O
) O
on O
cancer-related O
fatigue O
in O
women O
receiving O
breast O
cancer O
adjuvant O
chemotherapy O
treatment O
( O
CTX O
) O
. O

The B-Claim
efficacy I-Claim
of I-Claim
5-FU I-Claim
, I-Claim
modulated I-Claim
with I-Claim
6S-LV I-Claim
, I-Claim
is I-Claim
moderate I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
gastric I-Claim
carcinoma I-Claim
, I-Claim
similar I-Claim
to I-Claim
cisplatin-containing I-Claim
regimens I-Claim
. I-Claim

The B-Claim
study I-Claim
results I-Claim
suggest I-Claim
that I-Claim
K-tape I-Claim
could I-Claim
replace I-Claim
the I-Claim
bandage I-Claim
in I-Claim
DLT I-Claim
, I-Claim
and I-Claim
it I-Claim
could I-Claim
be I-Claim
an I-Claim
alternative I-Claim
choice I-Claim
for I-Claim
the I-Claim
breast-cancer-related I-Claim
lymphedema I-Claim
patient I-Claim
with I-Claim
poor I-Claim
short-stretch I-Claim
bandage I-Claim
compliance I-Claim
after I-Claim
1-month I-Claim
intervention I-Claim
. I-Claim

Patients B-Premise
in I-Premise
the I-Premise
standard I-Premise
treatment I-Premise
group I-Premise
showed I-Premise
a I-Premise
greater I-Premise
decline I-Premise
in I-Premise
Trial I-Premise
Outcome I-Premise
Index I-Premise
( I-Premise
TOI I-Premise
) I-Premise
scores I-Premise
( I-Premise
physical I-Premise
well-being I-Premise
, I-Premise
functional I-Premise
well-being I-Premise
and I-Premise
breast I-Premise
cancer I-Premise
concerns I-Premise
subscales I-Premise
in I-Premise
FACT-B+4 I-Premise
) I-Premise
and I-Premise
recovered I-Premise
more I-Premise
slowly I-Premise
than I-Premise
patients I-Premise
in I-Premise
the I-Premise
SNB I-Premise
group I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

QOL B-Claim
was I-Claim
similar I-Claim
for I-Claim
both I-Claim
arms I-Claim
. I-Claim

A O
proof O
of O
principle O
study O
was O
performed O
to O
investigate O
the O
efficacy O
of O
combing O
anti-aromatase O
therapy O
( O
exemestane O
) O
and O
COX-2 O
inhibitors O
neoadjuvantly O
. O

438 O
of O
439 O
men O
assigned O
endocrine O
treatment O
and O
434 O
of O
436 O
assigned O
endocrine O
plus O
radiotherapy O
completed O
at O
least O
one O
questionnaire O
. O

Postoperative O
quality O
of O
life O
( O
QOL O
) O
was O
evaluated O
between O
the O
2 O
methods O
by O
a O
multi-institutional O
prospective O
randomized O
trial O
. O

To O
determine O
the O
incremental O
cost O
utility O
of O
epoetin-alfa O
versus O
placebo O
in O
anaemic O
patients O
with O
stage O
IV O
breast O
cancer O
from O
a O
UK O
National O
Health O
Service O
perspective O
. O

There B-Premise
is I-Premise
a I-Premise
further I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
both I-Premise
uterine I-Premise
volume I-Premise
and I-Premise
dominant I-Premise
fibroid I-Premise
diameter I-Premise
between I-Premise
6 I-Premise
months I-Premise
and I-Premise
5 I-Premise
years I-Premise
after I-Premise
UAE I-Premise
. I-Premise

Notably O
, O
patients B-Premise
receiving I-Premise
FLO I-Premise
or I-Premise
FLOT I-Premise
as I-Premise
palliative I-Premise
treatment I-Premise
( I-Premise
n I-Premise
= I-Premise
98 I-Premise
) I-Premise
achieved I-Premise
comparable I-Premise
QOL I-Premise
results I-Premise
. I-Premise

Median B-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
9.2 I-Premise
months I-Premise
( I-Premise
FU/LV/bevacizumab I-Premise
) I-Premise
and I-Premise
5.5 I-Premise
months I-Premise
( I-Premise
FU/LV/placebo I-Premise
) I-Premise
";" I-Premise
hazard B-Premise
ratio I-Premise
was I-Premise
0.50 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.0002 I-Premise
. O

Similarly B-Premise
, I-Premise
both I-Premise
groups I-Premise
showed I-Premise
a I-Premise
decline I-Premise
in I-Premise
physical I-Premise
and I-Premise
functional I-Premise
well I-Premise
being I-Premise
but I-Premise
recovered I-Premise
in I-Premise
the I-Premise
3 I-Premise
months I-Premise
posttreatment I-Premise
follow-up I-Premise
, I-Premise
with I-Premise
the I-Premise
rhDNase I-Premise
group I-Premise
exhibiting I-Premise
speedier I-Premise
recovery I-Premise
. I-Premise

Therefore B-Claim
, I-Claim
this I-Claim
regimen I-Claim
is I-Claim
not I-Claim
recommended I-Claim
as I-Claim
standard I-Claim
of I-Claim
care I-Claim
treatment I-Claim
for I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

A B-Premise
statistically I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
resilience I-Premise
, I-Premise
perceived I-Premise
stress I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
and I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
at I-Premise
12 I-Premise
weeks I-Premise
, I-Premise
compared I-Premise
with I-Premise
baseline I-Premise
was I-Premise
observed I-Premise
in I-Premise
the I-Premise
study I-Premise
arm I-Premise
. I-Premise

Most B-Premise
participants I-Premise
found I-Premise
writing I-Premise
valuable I-Premise
and I-Premise
did I-Premise
not I-Premise
report I-Premise
any I-Premise
long-term I-Premise
negative I-Premise
effects I-Premise
. I-Premise

The B-Premise
ablation I-Premise
rate I-Premise
was I-Premise
equivalent I-Premise
between I-Premise
the I-Premise
( I-Premise
131 I-Premise
) I-Premise
I I-Premise
doses I-Premise
and I-Premise
between I-Premise
the I-Premise
thyrotropin-stimulation I-Premise
methods I-Premise
. I-Premise

No B-Premise
significant I-Premise
between-group I-Premise
differences I-Premise
were I-Premise
observed I-Premise
for I-Premise
fatigue I-Premise
, I-Premise
quality I-Premise
of I-Premise
life I-Premise
or I-Premise
psychological I-Premise
distress I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
postoperative I-Premise
RT I-Premise
had I-Premise
better I-Premise
function I-Premise
with I-Premise
higher I-Premise
MSTS I-Premise
( I-Premise
25.8 I-Premise
v I-Premise
21.3 I-Premise
, I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
, I-Premise
TESS I-Premise
( I-Premise
69.8 I-Premise
v I-Premise
60.6 I-Premise
, I-Premise
P I-Premise
=.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
SF-36 I-Premise
bodily I-Premise
pain I-Premise
( I-Premise
67.7 I-Premise
v I-Premise
58.5 I-Premise
, I-Premise
P I-Premise
=.03 I-Premise
) I-Premise
scores I-Premise
at I-Premise
6 I-Premise
weeks I-Premise
after I-Premise
surgery I-Premise
. I-Premise

Three B-Premise
of I-Premise
the I-Premise
quality-of-life I-Premise
domains I-Premise
showed I-Premise
trends I-Premise
toward I-Premise
increases I-Premise
in I-Premise
the I-Premise
exercise I-Premise
group I-Premise
: I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
P I-Premise
=.050 I-Premise
) I-Premise
, I-Premise
general I-Premise
health I-Premise
( I-Premise
P I-Premise
=.048 I-Premise
) I-Premise
, I-Premise
and I-Premise
vitality I-Premise
( I-Premise
P I-Premise
=.023 I-Premise
) I-Premise
. I-Premise

Serum B-Premise
albumin I-Premise
concentration I-Premise
declined I-Premise
by I-Premise
-1.2 I-Premise
g/L I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI= I-Premise
-2.0 I-Premise
to I-Premise
-0.4 I-Premise
) I-Premise
per I-Premise
4 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
but I-Premise
remained I-Premise
stable I-Premise
( I-Premise
0.0 I-Premise
g/L I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-0.3 I-Premise
to I-Premise
+0.3 I-Premise
) I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
( I-Premise
P I-Premise
=.006 I-Premise
) I-Premise
. I-Premise

For B-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
prostate I-Claim
cancer I-Claim
, I-Claim
treatment I-Claim
is I-Claim
primarily I-Claim
palliative I-Claim
, I-Claim
relying I-Claim
mainly I-Claim
on I-Claim
the I-Claim
suppression I-Claim
of I-Claim
systemic I-Claim
androgen I-Claim
hormone I-Claim
levels I-Claim
. I-Claim

At B-Premise
the I-Premise
six I-Premise
month I-Premise
follow-up I-Premise
, I-Premise
most I-Premise
of I-Premise
these I-Premise
effects I-Premise
were I-Premise
maintained I-Premise
and I-Premise
an I-Premise
intervention I-Premise
effect I-Premise
for I-Premise
breast I-Premise
cancer I-Premise
specific I-Premise
quality I-Premise
of I-Premise
life I-Premise
emerged I-Premise
. I-Premise

Oral B-Claim
doxifluridine I-Claim
with I-Claim
leucovorin I-Claim
shows I-Claim
a I-Claim
comparable I-Claim
therapeutic I-Claim
efficacy I-Claim
to I-Claim
intravenous I-Claim
5-FU I-Claim
regimen I-Claim
with I-Claim
high I-Claim
quality I-Claim
of I-Claim
life I-Claim
as I-Claim
postoperative I-Claim
adjuvant I-Claim
therapy I-Claim
. I-Claim

In O
this O
large O
randomized O
trial O
, O
thalidomide B-Claim
in I-Claim
combination I-Claim
with I-Claim
chemotherapy I-Claim
did I-Claim
not I-Claim
improve I-Claim
survival I-Claim
of I-Claim
patients I-Claim
with I-Claim
SCLC I-Claim
but I-Claim
was I-Claim
associated I-Claim
with I-Claim
an I-Claim
increased I-Claim
risk I-Claim
of I-Claim
thrombotic I-Claim
events I-Claim
. I-Claim

Vaginal B-Premise
dryness I-Premise
( I-Premise
b I-Premise
= I-Premise
0.064 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.016-0.112 I-Premise
) I-Premise
and I-Premise
sexual I-Premise
problems I-Premise
( I-Premise
b I-Premise
= I-Premise
0.054 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.007-0.102 I-Premise
) I-Premise
increased I-Premise
in I-Premise
women I-Premise
taking I-Premise
anastrozole I-Premise
compared I-Premise
with I-Premise
women I-Premise
taking I-Premise
tamoxifen I-Premise
. I-Premise

Capecitabine/docetaxel B-Claim
was I-Claim
a I-Claim
cost-effective I-Claim
treatment I-Claim
in I-Claim
patients I-Claim
with I-Claim
anthracycline-pretreated I-Claim
advanced I-Claim
breast I-Claim
carcinoma I-Claim
, I-Claim
and I-Claim
had I-Claim
an I-Claim
incremental I-Claim
cost-effectiveness I-Claim
ratio I-Claim
that I-Claim
compares I-Claim
very I-Claim
favorably I-Claim
with I-Claim
that I-Claim
of I-Claim
many I-Claim
other I-Claim
oncology I-Claim
therapies I-Claim
. I-Claim

The B-Claim
safer I-Claim
and I-Claim
simpler I-Claim
RY I-Claim
method I-Claim
may I-Claim
be I-Claim
a I-Claim
more I-Claim
suitable I-Claim
reconstruction I-Claim
method I-Claim
than I-Claim
INT I-Claim
after I-Claim
total I-Claim
gastrectomy I-Claim
. I-Claim

Changes B-Premise
from I-Premise
baseline I-Premise
in I-Premise
several I-Premise
quality I-Premise
of I-Premise
life I-Premise
variables I-Premise
were I-Premise
significantly I-Premise
different I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
periodically I-Premise
from I-Premise
months I-Premise
1 I-Premise
to I-Premise
6 I-Premise
, I-Premise
and I-Premise
all I-Premise
favored I-Premise
bicalutamide I-Premise
. I-Premise

Patients B-Premise
with I-Premise
extensive I-Premise
disease I-Premise
survived I-Premise
significantly I-Premise
longer I-Premise
with I-Premise
late I-Premise
alternating I-Premise
chemotherapy I-Premise
than I-Premise
on I-Premise
the I-Premise
early I-Premise
alternation I-Premise
regimen I-Premise
( I-Premise
median I-Premise
survival I-Premise
336 I-Premise
days I-Premise
versus I-Premise
301 I-Premise
days I-Premise
, I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

No B-Premise
difference I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
between I-Premise
topotecan I-Premise
and I-Premise
observation I-Premise
was I-Premise
observed I-Premise
at I-Premise
any I-Premise
assessment I-Premise
time I-Premise
or I-Premise
for I-Premise
any I-Premise
of I-Premise
the I-Premise
subscale I-Premise
scores I-Premise
. I-Premise

After B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
6.4 I-Premise
years I-Premise
, I-Premise
132 I-Premise
patients I-Premise
in I-Premise
the I-Premise
short-term I-Premise
group I-Premise
and I-Premise
98 I-Premise
in I-Premise
the I-Premise
long-term I-Premise
group I-Premise
had I-Premise
died I-Premise
";" I-Premise
the B-Premise
number I-Premise
of I-Premise
deaths I-Premise
due I-Premise
to I-Premise
prostate I-Premise
cancer I-Premise
was I-Premise
47 I-Premise
in I-Premise
the I-Premise
short-term I-Premise
group I-Premise
and I-Premise
29 I-Premise
in I-Premise
the I-Premise
long-term I-Premise
group I-Premise
. I-Premise

These B-Premise
findings I-Premise
are I-Premise
consistent I-Premise
with I-Premise
evidence I-Premise
that I-Premise
only I-Premise
the I-Premise
combined I-Premise
intervention I-Premise
yielded I-Premise
increases I-Premise
in I-Premise
both I-Premise
exercise I-Premise
and I-Premise
stress I-Premise
management I-Premise
activity I-Premise
. I-Premise

In B-Premise
the I-Premise
gefitinib I-Premise
250 I-Premise
mg/day I-Premise
, I-Premise
500 I-Premise
mg/day I-Premise
, I-Premise
and I-Premise
methotrexate I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
, I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
5.6 I-Premise
, I-Premise
6.0 I-Premise
, I-Premise
and I-Premise
6.7 I-Premise
months I-Premise
";" I-Premise
ORRs I-Premise
( I-Premise
Response I-Premise
Evaluation I-Premise
Criteria I-Premise
in I-Premise
Solid I-Premise
Tumors I-Premise
) I-Premise
were I-Premise
2.7 I-Premise
% I-Premise
, I-Premise
7.6 I-Premise
% I-Premise
and I-Premise
3.9 I-Premise
% I-Premise
, I-Premise
with I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
between I-Premise
either I-Premise
gefitinib I-Premise
arm I-Premise
and I-Premise
methotrexate I-Premise
. I-Premise

In B-Claim
advanced I-Claim
not I-Claim
selected I-Claim
NSCLC I-Claim
chemotherapy I-Claim
achieved I-Claim
an I-Claim
advantage I-Claim
of I-Claim
approximately I-Claim
1-2 I-Claim
months I-Claim
on I-Claim
median I-Claim
survival I-Claim
versus I-Claim
best I-Claim
supportive I-Claim
care I-Claim
. I-Claim

Overall B-Premise
, I-Premise
patients I-Premise
receiving I-Premise
goserelin I-Premise
alone I-Premise
showed I-Premise
a I-Premise
marked I-Premise
improvement I-Premise
or I-Premise
less I-Premise
deterioration I-Premise
in I-Premise
QOL I-Premise
measures I-Premise
over I-Premise
the I-Premise
first I-Premise
6 I-Premise
months I-Premise
than I-Premise
those I-Premise
patients I-Premise
treated I-Premise
with I-Premise
CMF I-Premise
. I-Premise

Preparatory B-Claim
education I-Claim
and I-Claim
support I-Claim
has I-Claim
the I-Claim
potential I-Claim
to I-Claim
assist I-Claim
women I-Claim
to I-Claim
cope I-Claim
with I-Claim
cancer-related I-Claim
fatigue I-Claim
in I-Claim
the I-Claim
short I-Claim
term I-Claim
. I-Claim

rhTSH-prepared B-Claim
patients I-Claim
maintained I-Claim
a I-Claim
higher I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
received I-Claim
less I-Claim
radiation I-Claim
exposure I-Claim
to I-Claim
the I-Claim
blood I-Claim
. I-Claim

In B-Claim
nonrandomized I-Claim
studies I-Claim
involving I-Claim
patients I-Claim
with I-Claim
different I-Claim
tumor I-Claim
types I-Claim
including I-Claim
non-small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
, I-Claim
ATP I-Claim
infusion I-Claim
appeared I-Claim
to I-Claim
inhibit I-Claim
loss I-Claim
of I-Claim
weight I-Claim
and I-Claim
deterioration I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
and I-Claim
performance I-Claim
status I-Claim
. I-Claim

IMRT B-Claim
results I-Claim
in I-Claim
clinically I-Claim
meaningful I-Claim
and I-Claim
statistically I-Claim
better I-Claim
QOL I-Claim
scores I-Claim
for I-Claim
some I-Claim
domains I-Claim
compared I-Claim
to I-Claim
3D-CRT I-Claim
at I-Claim
several I-Claim
time I-Claim
points I-Claim
with I-Claim
comparable I-Claim
disease I-Claim
outcomes I-Claim
that I-Claim
could I-Claim
support I-Claim
its I-Claim
widespread I-Claim
adoption I-Claim
in I-Claim
routine I-Claim
clinical I-Claim
practice I-Claim
. I-Claim

More B-Claim
efficient I-Claim
treatment I-Claim
protocol I-Claim
is I-Claim
needed I-Claim
for I-Claim
clinical I-Claim
practice I-Claim
. I-Claim

Future B-Claim
work I-Claim
is I-Claim
needed I-Claim
to I-Claim
improve I-Claim
the I-Claim
design I-Claim
and I-Claim
the I-Claim
planning I-Claim
of I-Claim
these I-Claim
interventions I-Claim
to I-Claim
improve I-Claim
program I-Claim
adherence I-Claim
. I-Claim

After B-Claim
major I-Claim
surgery I-Claim
, I-Claim
specialized I-Claim
supportive I-Claim
enteral I-Claim
and I-Claim
parenteral I-Claim
nutrition I-Claim
are I-Claim
not I-Claim
superior I-Claim
to I-Claim
oral I-Claim
nutrition I-Claim
only I-Claim
when I-Claim
guided I-Claim
by I-Claim
a I-Claim
dietitian I-Claim
. I-Claim

Le B-Claim
( I-Claim
y I-Claim
) I-Claim
is I-Claim
an I-Claim
attractive I-Claim
target I-Claim
since I-Claim
it I-Claim
is I-Claim
expressed I-Claim
by I-Claim
most I-Claim
NSCLC I-Claim
. I-Claim

The B-Claim
regimen I-Claim
of I-Claim
once I-Claim
every I-Claim
3 I-Claim
weeks I-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
significantly I-Claim
lower I-Claim
incidence I-Claim
of I-Claim
severe I-Claim
diarrhea I-Claim
. I-Claim

There B-Claim
is I-Claim
no I-Claim
rationale I-Claim
for I-Claim
the I-Claim
routine I-Claim
use I-Claim
of I-Claim
neuronavigation I-Claim
to I-Claim
improve I-Claim
the I-Claim
extent I-Claim
of I-Claim
tumor I-Claim
resection I-Claim
and I-Claim
prognosis I-Claim
in I-Claim
patients I-Claim
harboring I-Claim
a I-Claim
solitary I-Claim
enhancing I-Claim
intracerebral I-Claim
lesion I-Claim
when I-Claim
neuronavigation I-Claim
is I-Claim
not I-Claim
already I-Claim
deemed I-Claim
advantageous I-Claim
because I-Claim
of I-Claim
the I-Claim
size I-Claim
or I-Claim
location I-Claim
of I-Claim
the I-Claim
lesion I-Claim
. I-Claim

Patients B-Claim
given I-Claim
targeted I-Claim
intervention I-Claim
following I-Claim
a I-Claim
detailed I-Claim
clinical I-Claim
algorithm I-Claim
had I-Claim
better I-Claim
improvements I-Claim
in I-Claim
radiotherapy-induced I-Claim
gastrointestinal I-Claim
symptoms I-Claim
than I-Claim
did I-Claim
patients I-Claim
given I-Claim
usual I-Claim
care I-Claim
. I-Claim

Pamidronate B-Claim
treatment I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
efficaciously I-Claim
reduced I-Claim
skeletal I-Claim
morbidity I-Claim
. I-Claim

Improvements B-Claim
were I-Claim
seen I-Claim
for I-Claim
symptom I-Claim
scores I-Claim
over I-Claim
the I-Claim
study I-Claim
period I-Claim
. I-Claim

In B-Claim
minimally I-Claim
symptomatic I-Claim
patients I-Claim
with I-Claim
locally I-Claim
advanced I-Claim
non-small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
, I-Claim
no I-Claim
persuasive I-Claim
evidence I-Claim
was I-Claim
found I-Claim
to I-Claim
indicate I-Claim
that I-Claim
giving I-Claim
immediate I-Claim
palliative I-Claim
thoracic I-Claim
radiotherapy I-Claim
improves I-Claim
symptom I-Claim
control I-Claim
, I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
or I-Claim
survival I-Claim
when I-Claim
compared I-Claim
with I-Claim
delaying I-Claim
until I-Claim
symptoms I-Claim
require I-Claim
treatment I-Claim
. I-Claim

To B-Claim
our I-Claim
knowledge I-Claim
, I-Claim
this I-Claim
study I-Claim
provided I-Claim
novel I-Claim
evidence I-Claim
that I-Claim
MBSR I-Claim
can I-Claim
help I-Claim
alleviate I-Claim
long-term I-Claim
emotional I-Claim
and I-Claim
physical I-Claim
adverse I-Claim
effects I-Claim
of I-Claim
medical I-Claim
treatments I-Claim
, I-Claim
including I-Claim
endocrine I-Claim
treatments I-Claim
. I-Claim

Bevacizumab B-Claim
, I-Claim
a I-Claim
humanized I-Claim
monoclonal I-Claim
antibody I-Claim
against I-Claim
vascular I-Claim
endothelial I-Claim
growth I-Claim
factor I-Claim
( I-Claim
VEGF I-Claim
) I-Claim
, I-Claim
has I-Claim
been I-Claim
shown I-Claim
to I-Claim
be I-Claim
efficient I-Claim
in I-Claim
suppressing I-Claim
the I-Claim
accumulation I-Claim
of I-Claim
pleural I-Claim
fluid I-Claim
. I-Claim

Thus B-Claim
, I-Claim
funds I-Claim
permitting I-Claim
, I-Claim
oral I-Claim
Etoposide I-Claim
is I-Claim
a I-Claim
pragmatic I-Claim
approach I-Claim
to I-Claim
treating I-Claim
EKS I-Claim
in I-Claim
an I-Claim
environment I-Claim
where I-Claim
antiretroviral I-Claim
drugs I-Claim
are I-Claim
not I-Claim
universally I-Claim
available I-Claim
. I-Claim

In B-Claim
contrast I-Claim
, I-Claim
if I-Claim
their I-Claim
cancer I-Claim
was I-Claim
ER-positive I-Claim
( I-Claim
i.e. I-Claim
, I-Claim
endocrine-responsive I-Claim
) I-Claim
, I-Claim
they I-Claim
obtained I-Claim
no I-Claim
benefit I-Claim
from I-Claim
the I-Claim
combination I-Claim
treatment I-Claim
compared I-Claim
with I-Claim
tamoxifen I-Claim
alone I-Claim
. I-Claim

Scapula-oriented B-Claim
exercise I-Claim
had I-Claim
beneficial I-Claim
effects I-Claim
on I-Claim
pain I-Claim
, I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
aspects I-Claim
of I-Claim
strength I-Claim
. I-Claim

We O
conclude O
that O
three B-Claim
cycles I-Claim
of I-Claim
BEP I-Claim
, I-Claim
with I-Claim
etoposide I-Claim
at I-Claim
500 I-Claim
mg/m I-Claim
( I-Claim
2 I-Claim
) I-Claim
, I-Claim
is I-Claim
sufficient I-Claim
therapy I-Claim
in I-Claim
good-prognosis I-Claim
germ I-Claim
cell I-Claim
cancer I-Claim
and O
that O
the B-Claim
administration I-Claim
of I-Claim
the I-Claim
chemotherapy I-Claim
in I-Claim
3 I-Claim
days I-Claim
has I-Claim
no I-Claim
detrimental I-Claim
effect I-Claim
on I-Claim
the I-Claim
effectiveness I-Claim
of I-Claim
the I-Claim
BEP I-Claim
regimen I-Claim
. I-Claim

Patients B-Claim
who I-Claim
underwent I-Claim
gastric I-Claim
tube I-Claim
reconstruction I-Claim
develop I-Claim
less I-Claim
postoperative I-Claim
digestive I-Claim
tract I-Claim
complications I-Claim
, I-Claim
and I-Claim
have I-Claim
a I-Claim
quicker I-Claim
recovery I-Claim
and I-Claim
a I-Claim
better I-Claim
QoL I-Claim
during I-Claim
the I-Claim
follow-up I-Claim
period I-Claim
. I-Claim

The B-Claim
superiority I-Claim
of I-Claim
combination I-Claim
therapy I-Claim
over I-Claim
monochemotherapy I-Claim
has I-Claim
not I-Claim
been I-Claim
demonstrated I-Claim
convincingly I-Claim
. I-Claim

No B-Claim
difference I-Claim
in I-Claim
QOL I-Claim
was I-Claim
observed I-Claim
. I-Claim

On B-Claim
the I-Claim
basis I-Claim
of I-Claim
our I-Claim
trial I-Claim
and I-Claim
the I-Claim
meta-analysis I-Claim
, I-Claim
GEM-CAP I-Claim
should I-Claim
be I-Claim
considered I-Claim
as I-Claim
one I-Claim
of I-Claim
the I-Claim
standard I-Claim
first-line I-Claim
options I-Claim
in I-Claim
locally I-Claim
advanced I-Claim
and I-Claim
metastatic I-Claim
pancreatic I-Claim
cancer I-Claim
. I-Claim

Genotypes B-Claim
of I-Claim
glutathione-related I-Claim
enzymes I-Claim
, I-Claim
especially I-Claim
GCLC I-Claim
, I-Claim
may I-Claim
be I-Claim
used I-Claim
as I-Claim
host I-Claim
factors I-Claim
in I-Claim
predicting I-Claim
patients I-Claim
' I-Claim
survival I-Claim
after I-Claim
platinum-based I-Claim
chemotherapy I-Claim
. I-Claim

